NCT02682407 - Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

IgANLupus NephritisMNC3 Glomerulopathy

Interventions

BIOLOGICAL

OMS721 (narsoplimab)

Biological: OMS721 (narsoplimab)

Trial Locations (12)

11355

ACTIVE_NOT_RECRUITING

Omeros Investigational Site, Flushing

30046

ACTIVE_NOT_RECRUITING

Omeros Investigational Site, Lawrenceville

30909

ACTIVE_NOT_RECRUITING

Omeros Investigational Site, Augusta

53226

ACTIVE_NOT_RECRUITING

Omeros Investigational Site, Milwaukee

60805

ACTIVE_NOT_RECRUITING

Omeros Investigational Site, Evergreen Park

78215

ACTIVE_NOT_RECRUITING

Omeros Investigational Site, San Antonio

80230

ACTIVE_NOT_RECRUITING

Omeros Investigational Site, Denver

08043

ACTIVE_NOT_RECRUITING

Omeros Investigational Site, Voorhees Township

Unknown

RECRUITING

Omeros Investigational Site, Chai Wan

RECRUITING

Omeros Investigational Site, Hong Kong

NOT_YET_RECRUITING

Omeros Investigational Site, Kowloon

RECRUITING

Omeros Investigational Site, Shatin